Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by DrHolidayon Jun 24, 2018 4:05pm
100 Views
Post# 28221061

The elusive butterfly of love

The elusive butterfly of love"Oh, Hoto is going dancing to LaLaland to pick daisies and buttercups and chase elusive PDP butterflies now that he is out of ICO, and then to sow doubt here while pumping up his new play".

It would appear that he himself has forgotten the bullish investment case for ICO, or is he a scalper in reality merely trying to bash ICO lower for a repurchase? If you follow the money, you will realize that the big players did indeed take a profit, but understand the size of the market and how Oral B Amphotericin could be a game changer and challenge Gilead's  billion dollar market share for the injectable version which has been around for 50 years. If you think that AstraZeneca has no interest in Oral B, then you are sadly mistaken. I don't know when the US32 million dollar milestone payment option must be paid. It might not be until successful Phase 3 trials. Meanwhile, ICO could easily do a small financing at a premium to the market and close it in a done deal in a heartbeat just to tide them over to continue work and proceed to Phase 2.

Mark my words that AstraZeneca will be watching ICO for phase 1 trial results in July, and taking
an eqity stake in ICO would be a strategic move, and help to defend against any hostility by unfriendly competitors who do not want to lose market share to Oral B Amphotericin.

https://www.youtube.com/watch?v=2JyMGb-d8Io
<< Previous
Bullboard Posts
Next >>